317 articles
Beloranib
Beloranib (CKD-732, ZGN-440, ZGN-433): fumagillin-analogue MetAP2 inhibitor obesity drug by Zafgen and Chong Kun Dang; effective in trials but halted in 2015 after fatal pulmonary embolisms.
Bempedoic acid
Bempedoic acid (Nexletol, Nilemdo; with ezetimibe as Nexlizet, Nustendi) is an oral ATP citrate lyase inhibitor lowering LDL-C; CLEAR Outcomes showed 13% fewer major cardiovascular events in statin-intolerant patients.
Benfluorex
Benfluorex (Mediator), a fenfluramine-derivative appetite suppressant and antidiabetic add-on drug marketed by Servier from 1976, withdrawn in France in 2009 and the EU in 2010 for causing 5-HT2B-mediated valvular heart disease.
Benfotiamine
Benfotiamine (S-benzoylthiamine O-monophosphate), a lipid-soluble synthetic thiamine (vitamin B1) derivative with higher bioavailability, activating transketolase; used for diabetic peripheral neuropathy in some countries and in trials for early Alzheimer's disease.
Benzbromarone
Benzbromarone (Desuric, Urinorm) is a benzofuran uricosuric drug first marketed in the 1970s to treat gout; it was withdrawn in Europe in 2003 over hepatotoxicity concerns.
Benzphetamine
Benzphetamine (Didrex) is a US Schedule III sympathomimetic amine anorectic, approved in 1960, used short-term with diet for obesity (BMI 30+), dosed 25-50 mg one to three times daily; brand discontinued, generics remain.
Bexagliflozin
Bexagliflozin (Brenzavvy; Bexacat in cats) is an SGLT2 inhibitor approved by the FDA on January 20, 2023, dosed 20 mg daily as adjunct to diet and exercise for adult type 2 diabetes, notable for low cost and no cardiovascular outcomes trial.
Bezafibrate
Bezafibrate is a fibrate-class lipid-lowering drug, available in Europe since 1977 under trade names including Bezalip, used as an adjunct to diet when statins are contraindicated.
BGM0504
BGM0504 is BrightGene's investigational once-weekly injectable dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes, with phase 3 weight loss of 19.3% and an NDA accepted in China in June 2026.
BGR-34
BGR-34 (NBRMAP-DB) is an Ayurvedic six-herb tablet for type 2 diabetes developed by CSIR-CIMAP and CSIR-NBRI, licensed to AIMIL Pharmaceuticals, sold in India since 2015 amid disputed clinical evidence.
Bile acid sequestrant
Bile acid sequestrants (BAS, bile acid resins): cholestyramine, colestipol, colesevelam. Non-absorbed cationic polymer gels binding bile acids in the gut, lowering LDL-C 15-30%, also improving glycemic control.
Bixalomer
Bixalomer (ASP1585, AMG 223, ILY-101; Kiklin) is a non-calcium, metal-free amine polymer phosphate binder by Astellas/Ilypsa for hyperphosphatemia in hemodialysis, non-inferior to sevelamer HCl and reducing coronary calcification versus calcium carbonate.
Bocidelpar
Bocidelpar (ASP0367, bocidelpar sulfate, formerly MA-0211) is an oral selective PPARδ modulator by Astellas/Mitobridge for mitochondrial myopathy and DMD; phase 2 MOUNTAINSIDE was terminated.
Bofanglutide
Bofanglutide (博凡格鲁肽, GZR18) is Gan & Lee's investigational biweekly GLP-1 receptor agonist for obesity, type 2 diabetes, and OSA; GRADUAL-1 showed 18.54% weight loss at 52 weeks, with NMPA marketing application accepted September 2026.
Buformin
Buformin (1-butylbiguanide) is a biguanide antidiabetic drug reported in 1958 by Beringer, used mainly in Germany, and withdrawn in most countries in the late 1970s for lactic acidosis risk; it remains available in Romania.
BW-20829 (DII235)
BW-20829 (DII235) is an investigational GalNAc siRNA from Argo Biopharma, licensed to Novartis, that silences hepatic Lp(a) production; first patient dosed January 2026 in the global Phase 2b trial NCT07235046.
Caficrestat
Caficrestat (AT-001) is an orally active, highly selective aldose reductase inhibitor from Applied Therapeutics tested in the Phase 3 ARISE-HF trial for diabetic cardiomyopathy; the primary endpoint was not met.
Calcium glubionate anhydrous
Calcium glubionate anhydrous (calcium gluconogalactogluconate, UNII 3CF7K0SD0Q) is a water-soluble calcium salt of gluconic and lactobionic acids used as an oral syrup and injectable supplement for hypocalcemia, with only 7% elemental calcium by weight.
Calcium gluceptate
Calcium gluceptate, also known by the international nonproprietary name calcium glucoheptonate, is a soluble calcium salt used as a supplement to treat and prevent hypocalcemia.
Canagliflozin
Canagliflozin (Invokana) is an SGLT2 inhibitor approved in the US in 2013 for type 2 diabetes, later for cardiovascular and kidney risk reduction; CANVAS and CREDENCE trials established its benefits, and its 2017 amputation boxed warning was removed in 2020.
Carbimazole
Carbimazole, a thionamide prodrug of methimazole (thiamazole), treats hyperthyroidism by inhibiting thyroid hormone synthesis. UK/Europe standard first-line drug for Graves' disease; not approved in the US; key risks agranulocytosis, pancreatitis, teratogenicity.
Carglumic acid
Carglumic acid (Carbaglu, Ucedane; N-carbamoyl-L-glutamic acid) is an N-acetylglutamate analogue that activates CPS1 to treat hyperammonaemia in NAGS deficiency and organic acidaemias, dosed 100-250 mg/kg/day.
Centimizone
Centimizone (INN Mipinazole, also spelled Mipnazole) is an antithyroid imidazole, 1-propan-2-ylimidazolidine-2-thione, discovered at CSIR-CDRI Lucknow, approved in India in 1972, licensed to Unichem, but never marketed.
Cerivastatin
Cerivastatin (Baycol, Lipobay), Bayer's potent HMG-CoA reductase inhibitor statin for hypercholesterolemia, withdrawn in 2001-2002 after fatal rhabdomyolysis cases, especially with gemfibrozil.
Cetagliptin phosphate
Cetagliptin phosphate is a DPP-4 inhibitor for type 2 diabetes developed by CGeneTech in Suzhou, China, approved in December 2024 as a Class 1 innovative drug.
Chiglitazar sodium
Chiglitazar sodium, brand name Bilessglu and research code CS-038, is a PPAR pan-agonist drug developed in China and approved in 2021 to improve glycemic control in adults with type 2 diabetes.
Chlorotrianisene
Chlorotrianisene (Tace, CAS 569-57-3) is a synthetic non-steroidal triphenylethylene estrogen and prodrug, once used for menopausal symptoms, prostate cancer palliation, and lactation suppression; now discontinued and Prop 65 listed.
Cilofexor
Cilofexor (GS-9674, formerly Px-104) is an oral nonsteroidal agonist of the farnesoid X receptor developed by Gilead for liver diseases, whose phase 3 PSC trial ended early for futility.
Cinacalcet
Cinacalcet (Sensipar, Mimpara) is a calcimimetic, a positive allosteric modulator of the calcium-sensing receptor; first FDA-approved calcimimetic (2004) and first approved allosteric GPCR modulator, used for dialysis-related secondary hyperparathyroidism and hypercalcemia.
Ciprofibrate
Ciprofibrate (Lipanor, Modalim) is a fibrate lipid-lowering drug and PPARα agonist, dosed 100 mg once daily in Europe for severe hypertriglyceridaemia and mixed hyperlipidaemia when statins are unsuitable; not FDA-approved.